Sulodexide for the Prevention of Recurrent Venous Thromboembolism: The Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

2016 ◽  
Vol 4 (4) ◽  
pp. 536 ◽  
Author(s):  
G.M. Andreozzi ◽  
A.A. Bignamini ◽  
G. Davi
Keyword(s):  
Deep Vein Thrombosis ◽  
Venous Thromboembolism ◽  
Secondary Prevention ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Vein Thrombosis ◽  
Recurrent Venous Thromboembolism ◽  
Recurrent Deep Vein Thrombosis ◽  
Deep Vein

A Randomised, Double-Blind, Placebo-Controlled Trial of Dermatan Sulphate for Prevention of Deep Vein Thrombosis in Hip Fracture

1992 ◽  
Vol 67 (02) ◽  
pp. 203-208 ◽  
Author(s):  
Giancarlo Agnelli ◽  
Benilde Cosmi ◽  
Paolo Di Filippo ◽  
Valeria Ranucci ◽  
Franca Veschi ◽  
...  
Keyword(s):  
Deep Vein Thrombosis ◽  
Hip Fracture ◽  
Controlled Trial ◽  
Second Phase ◽  
Dermatan Sulphate ◽  
Heparin Cofactor Ii ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Vein Thrombosis ◽  
Deep Vein

SummaryDermatan sulphate (MF 701) is a natural glycosaminoglycan that catalyses thrombin inhibition by heparin cofactor II. The aim of the study was to evaluate the efficacy and safety of MF 701 for prevention of deep vein thrombosis (DVT) in patients with hip fracture. A randomised, double-blind, placebo-controlled design was used to assess two dose regimens of MF 701 in two consecutive study phases. Treatment was started within 48 h from the trauma and continued for 14 days for non-operated patients or until the 10th postoperative day. Bilateral mandatory venography was used to assess the end-point. Eighty patients were included in the first phase (40 MF 701, 40 placebo). MF 701, 100 mg IM b. i. d., did not reduce incidence of DVT from that on placebo and did not induce any bleeding. In the second phase 126 patients were included, with a randomisation ratio of 2:1 (84 MF 701, 300 mg IM b.i.d., 42 placebo). Bilateral venography was obtained for 110 patients. The incidence of DVT was 64% (23/36) in the placebo group and 38% (28/74) in the MF 701 group (p = 0.01; odds ratio [OR] = 0.34, 95% confidence limits [CL] = 0.15-0.80); proximal DVTs were 42% (15/36) and 20% (15/74), respectively (p = 0.02; OR = 0.36, CL = 0.15-0.89). No significant differences were found in haemorrhagic complications (2.4% in each group), blood loss from drains, blood transfusions, haemoglobin and haematocrit values. This study is the first demonstration that dermatan sulphate is a clinically effective antithrombotic agent without bleeding effects. It also provides evidence of the biological role of heparin cofactor II.

scholarly journals Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial

2016 ◽  
Vol 3 (12) ◽  
pp. e556-e562 ◽  
Author(s):  
Marc Righini ◽  
Jean-Philippe Galanaud ◽  
Hervé Guenneguez ◽  
Dominique Brisot ◽  
Antoine Diard ◽  
...  
Keyword(s):  
Deep Vein Thrombosis ◽  
Anticoagulant Therapy ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Vein Thrombosis ◽  
Deep Vein

Risk of recurrent venous thromboembolism among deep vein thrombosis and pulmonary embolism patients treated with warfarin

2014 ◽  
Vol 31 (3) ◽  
pp. 439-447 ◽  
Author(s):  
Beth L. Nordstrom ◽  
Michael A. Evans ◽  
Brian R. Murphy ◽  
Edith A. Nutescu ◽  
Jeff R. Schein ◽  
...  
Keyword(s):  
Pulmonary Embolism ◽  
Deep Vein Thrombosis ◽  
Venous Thromboembolism ◽  
Vein Thrombosis ◽  
Recurrent Venous Thromboembolism ◽  
Deep Vein

scholarly journals Metabolic syndrome increases risk of venous thromboembolism recurrence after acute deep vein thrombosis

2020 ◽  
Vol 4 (1) ◽  
pp. 127-135 ◽  
Author(s):  
Lauren K. Stewart ◽  
Jeffrey A. Kline
Keyword(s):  
Metabolic Syndrome ◽  
Deep Vein Thrombosis ◽  
Venous Thromboembolism ◽  
Large Population ◽  
Rank Statistic ◽  
Explanatory Variables ◽  
Vein Thrombosis ◽  
Kaplan Meier ◽  
Recurrent Venous Thromboembolism ◽  
Deep Vein

Abstract An improved understanding of which patients are at higher risk of recurrent venous thromboembolism (VTE) is important to designing interventions to reduce degraded quality of life after VTE. Although metabolic syndrome (MetS), the clustering of hypertension, hyperlipidemia, diabetes mellitus, and obesity has been associated with a hypofibrinolytic state, data linking VTE recurrence with MetS remain limited. The purpose of this study was to measure the prevalence of MetS in patients with deep vein thrombosis (DVT) across a large population and determine its effect on VTE recurrence. This was a retrospective analysis of a large statewide database from 2004 to 2017. We measured the frequency with which patients with DVT carried a comorbid International Coding of Diseases diagnosis of MetS components. Association of MetS with VTE recurrence was tested with a multiple logistic regression model and VTE recurrence as the dependent variable. Risk of VTE recurrence conferred by each MetS component was assessed by Kaplan-Meier curves with the log-rank statistic. A total of 151 054 patients with DVT were included in this analysis. Recurrence of VTE occurred in 17% overall and increased stepwise with each criterion for MetS. All 4 components of MetS had significant adjusted odds ratios (OR) for VTE recurrence, with hyperlipidemia having the largest (OR, 1.8), representing the 4 largest ORs of all possible explanatory variables. All 4 MetS variables were significant on Kaplan-Meier analysis for recurrence of VTE. These data imply a role for appropriate therapies to reduce the effects of MetS as a way to reduce risk of VTE recurrence.

scholarly journals Evaluating the Role of Compression Stockings in Preventing Post thrombotic Syndrome: A Review of the Literature

Thrombosis ◽  
2012 ◽  
Vol 2012 ◽  
pp. 1-9 ◽  
Author(s):  
Abir O. Kanaan ◽  
Jayne E. Lepage ◽  
Shabdis Djazayeri ◽  
Jennifer L. Donovan
Keyword(s):  
Risk Factors ◽  
Controlled Trial ◽  
Postthrombotic Syndrome ◽  
Review Of The Literature ◽  
Compression Stockings ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Vein Thrombosis ◽  
Deep Vein

Background. Postthrombotic syndrome (PTS) is a burdensome and costly complication of deep vein thrombosis (DVT). Up to 50% of patients with DVT will develop the disease within two years following the diagnosis of acute DVT. Various risk factors for developing PTS have been identified and different modalities have been used to prevent its development. Compression stockings have been studied for the prevention of PTS in patients diagnosed with proximal DVT. Methods. MEDLINE and EMBASE databases were searched to identify relevant original articles. Results. Several trials including two metaanalyses have examined the role of compression stockings for the prevention of PTS. Although most trials showed significant reduction in the development of PTS with the use of compression stockings, limitations in study design prevent the generalizability of the data. Two studies supported an individualized tailored duration especially in patients at low risk for developing the syndrome. A randomized double-blind placebo-controlled trial involving 800 patients is currently ongoing and may confirm the results of older studies. Conclusions. Clinical trials support the use of compression stockings in patients diagnosed with proximal DVT for the prevention of PTS.

An Assessment Of Subcutaneous Ancrod In Prevention Of Deep Vein Thrombosis After Surgery For Hip Replacement

1981 ◽  
Vol 46 (01) ◽  
pp. 093-093
Author(s):  
J Belch ◽  
D Meek ◽  
G Lowe ◽  
M Drummond ◽  
A Campbell ◽  
...  
Keyword(s):  
Deep Vein Thrombosis ◽  
Hip Replacement ◽  
Controlled Trial ◽  
Placebo Patient ◽  
Post Mortem ◽  
Double Blind ◽  
Subcutaneous Injections ◽  
Vein Thrombosis ◽  
High Incidence ◽  
Deep Vein

There is a high incidence of deep vein thrombosis (DVT) and pulmonary embolism (PTE) amongst patients undergoing surgery for hip replacement. We have assessed the use of ancrod (Arvin), a de- fibrinating enzyme in the prophylaxis of DVT.In a randomised double-blind controlled trial 35 patients received daily subcutaneous injections of ancrod after operation for hip replacement and 38 patients received saline injections. DVT was detected by bilateral ascending venography (68 patients) or post-mortem (1 patient) 7-19 days after surgery. The frequency of major femoral DVT (> 5 cm long) was significantly reduced from 18 thrombi in the limbs of the placebo group to 5 in the ancrod group ( p<0.05). Major bilateral femoral DVT were similarly reduced from 7 to 1 patients by treatment with ancrod.The overall frequency of all thrombi, including calf DVT, was however not significantly different between the groups. 5 patients had evidence of PTE (3 placebo, 2 ancrod). 6 patients within the ancrod group had evidence of increased wound bleeding, compared with one placebo patient, but in only one patient was this considered severe enough to require cessation of ancrod injections. As the majority of PTE perhaps arise from large femoral thrombi it would seem that ancrod prophylaxis, by reducing thrombus size, could aid the reduction of PTE in this group of patients.

Sign in / Sign up

Export Citation Format

Share Document